Therefore, the high expression of MALAT-1 in tumor tissue was related to clinicopathological features of NSCLC with regard to the high heterogeneity observed in tumor size (I2 = 60.5%), LNM (I2 = 83.1%), and TNM stage (I2 = 60.6%). This evidence concerns the gene MALAT1 and non-small cell lung carcinoma.